The FDA just signed off on a For­mu­la 1 piv­otal track for Sage's post­par­tum de­pres­sion drug

Sage Ther­a­peu­tics says the FDA has signed off on an as­ton­ish­ing­ly short clin­i­cal de­vel­op­ment path­way for post­par­tum de­pres­sion which may al­low for an ap­proval af­ter …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER